HIFU Ablation

In: Adenomyosis · 2021 · pp. 129–135 · doi:10.1007/978-981-33-4095-4_14 · W4233427881
book-chapter OA: closed CC0
Full text JSON View on OpenAlex View at publisher
AI-generated summary by claude@2026-06+body, 2026-06-10

This chapter illustrates the use of an ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation system for treating adenomyosis, detailing preoperative preparation and the therapeutic process.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text

The paper describes ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation for adenomyosis, contrasting it with magnetic resonance–guided HIFU (MRgHIFU) and emphasizing that ultrasound monitoring is less expensive and can provide real-time observation of uterine position and bowel movement during treatment. It reports that therapeutic effects at target lesions can be assessed via gray-scale changes on ultrasound, along with absence of Doppler blood flow and lack of perfusion of ultrasound contrast agent at adenomyosis lesions, which the chapter presents as reliable monitoring indicators. A major caveat stated is that the chapter provides an illustrative description of the therapeutic process and monitoring approach rather than presenting comparative efficacy data or detailed study limitations. This paper is centrally about endometriosis and adenomyosis — it specifically focuses on adenomyosis using ultrasound-guided HIFU ablation and the ultrasound monitoring indicators for lesion effect.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 2,425 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Ultrasound monitoring is the method to apply diagnostic imaging technology to guide the treatment of high-intensity focused ultrasound (HIFU). The treatment is called ultrasound-guided HIFU (USgHIFU) ablation surgery. Compared with focused ultrasound ablation surgery guided by magnetic resonance (MRgHIFU), HIFU under ultrasound monitoring is less expensive. Besides, ultrasound monitoring can also provide real-time image monitoring of changes in uterine position and bowel movement during the ablation procedure. The therapeutic effect can be shown by the gray-scale changes at the target lesions during HIFU ablation. Under ultrasound monitoring, all these gray-scale changes, absence of Doppler blood flow, and non-perfusion of ultrasound contrast agent at the adenomyosis lesion will indicate the effects of HIFU; thus, it is a reliable monitoring indicator [1]. In addition, ultrasound monitoring is quieter, and patients do not need to be in a relatively enclosed treatment environment, like in an MRI room. Therefore we are illustrating the use of a USgHIFU ablation system, which is more popular in China. In this chapter, we will introduce the preoperative preparation and the therapeutic process of focused ultrasound ablation surgery for adenomyosis. Access this chapter Tax calculation will be finalised at checkout Purchases are for personal use only Similar content being viewed by others

References

Orsi F, et al. High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations. Am J Roentgenol. 2010;195(3):W245–52. Zhang L, et al. Ultrasound-guided high intensity focused ultrasound for the treatment of gynaecological diseases: a review of safety and efficacy. Int J Hyperth. 2015;31(3):280–4. Author information Authors and Affiliations Corresponding author Editor information Editors and Affiliations Rights and permissions Copyright information © 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. About this chapter Cite this chapter Zhu, X., Wong, F., Xue, M. (2021). HIFU Ablation. In: Xue, M., Leng, J., Wong, F. (eds) Adenomyosis. Springer, Singapore. https://doi.org/10.1007/978-981-33-4095-4_14 Download citation DOI: https://doi.org/10.1007/978-981-33-4095-4_14 Published: Publisher Name: Springer, Singapore Print ISBN: 978-981-33-4094-7 Online ISBN: 978-981-33-4095-4 eBook Packages: MedicineMedicine (R0)

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (2)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
unpaywall
last seen: 2026-05-20T11:00:21.680559+00:00
License: CC0 · commercial use OK